Form 4: BridgeBio Pharma Director Sells Over 4,700 Shares in Recent Transactions
Insider Trading Disclosure
Hannah Valantine, a Director at BridgeBio Pharma, Inc., reported the sale of 4,707 shares of common stock across multiple transactions on June 26, 2025, totaling approximately $207,336.
Summary
- Hannah Valantine, a Director of BridgeBio Pharma, Inc. (BBIO), reported multiple sales of common stock on June 26, 2025.
- A total of 4,707 shares were sold across four separate transactions.
- The sales included 876 shares at a weighted average price of $44.1099, 1,542 shares at $44.01, 398 shares at a weighted average price of $44.1263, and 1,891 shares at $44.0303.
- The estimated total value of these sales is approximately $207,336.57.
- Following these transactions, Hannah Valantine directly holds 7,465 shares and indirectly holds 398 shares through a spouse.
Sentiment
Score: 5
Explanation: The document reports routine insider stock sales by a director for personal financial planning, which is a neutral event for the company's operational performance. While insider selling can sometimes be viewed with slight caution by investors, the reported volume is not indicative of a significant negative signal.
Negatives
- Insider selling, even for personal financial planning, can sometimes be perceived by the market as a slight negative signal, potentially suggesting a lack of confidence, although this is not always the case.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- The reported sales are transactions by a director, who is considered a related party. These include direct sales of common stock by Hannah Valantine and indirect sales through a spouse.
Stakeholder Impact
- Shareholders: May interpret the insider selling as a slight negative signal, though it is often for personal financial planning. The impact is likely minimal unless a pattern of significant insider selling emerges.
Key Dates
| Date | Description |
|---|---|
| 06/26/2025 | Date of earliest transaction for common stock sales by Hannah Valantine. |
| 06/30/2025 | Date the Form 4 filing was signed by Hannah A. Valantine, M.D. |
Recommendation
holdKeywords
BridgeBio Pharma, BBIO, SEC Form 4, Insider Trading, Stock Sale, Director Transaction, Hannah Valantine, Common Stock, Equity Sales
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.